Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data

J Thromb Haemost. 2023 Jun;21(6):1519-1528.e2. doi: 10.1016/j.jtha.2023.01.030. Epub 2023 Feb 3.

Abstract

We aimed to assess the relationship between residual pulmonary vascular obstruction (RPVO) on planar lung scan after completion of at least 3 months of anticoagulant therapy for acute pulmonary embolism (PE) and the risk of recurrent venous thromboembolism (VTE) or death due to PE one year after treatment discontinuation. The systematic review was registered with the International Prospective Registry of Systematic Reviews (PROSPERO: CRD42017081080). The primary outcome measure was to generate a pooled estimate of the rate of recurrent VTE at one year in patient with RPVO diagnosed on planar lung scan after discontinuation of at least 3 months of anticoagulant treatment for an acute PE. Individual data were obtained for 809 patients. RPVO (ie, obstruction >0%) was found in 407 patients (50.3%) after a median of 6.6 months of anticoagulant therapy for a first acute PE. Recurrent VTE or death due to PE occurred in 114 patients (14.1%), for an annual risk of 6.4% (95% confidence interval, 4.7%-8.6%). Out of the 114 recurrent events, 63 occurred within one year after discontinuation of anticoagulant therapy corresponding to a risk of 8.1% (6.4%-9.8%) at 1 year. The risk of recurrent VTE at one year was 5.8% (4.4-7.2) in participants with RPVO <5%, vs 11.7% (9.5-13.8) in participants with RPVO ≥5%. RPVO is a significant predictor of the risk of recurrent venous thromboembolism. However, the risk of recurrent events remains too high in patients without residual perfusion defect for it to be used as a stand-alone test to decide on anticoagulation discontinuation.

Keywords: lung scintigraphy; pulmonary embolism; recurrent venous thromboembolism; residual pulmonary vascular obstruction.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Anticoagulants / adverse effects
  • Humans
  • Lung / blood supply
  • Pulmonary Artery
  • Pulmonary Embolism* / diagnosis
  • Pulmonary Embolism* / drug therapy
  • Recurrence
  • Risk Factors
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / drug therapy

Substances

  • Anticoagulants